Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin

Mariaelena Pistoni, Giulia Tondelli, Cristina Gallo, Federica Torricelli, Alessandra Maresca, Valerio Carelli, Alessia Ciarrocchi, Katiuscia Dallaglio

Research output: Contribution to journalArticle

Abstract

Therapeutic failures in cancer therapy are often associated with metabolic plasticity. The use of metabolic modulators as anti-cancer agents has been effective in correcting metabolic alterations; however, molecular events behind metabolic switch are still largely unexplored. Herein, we characterize the molecular and functional events that follow prolonged oxidative phosphorylation inhibition by phenformin in order to study how melanoma cells adapt to this specific metabolic pressure. We show that melanoma cells cultured up to 3 months with high doses of phenformin (R-cells) are less viable and migrate and invade less than parental (S-) cells. Microarray analysis of R-melanoma cells reveals a switch in the energy production strategy accompanied by the modulation of several immunological-associated genes. R-cells display low oxygen consumption rate and high basal extracellular acidification rate. When treated with vemurafenib, R-cell viability, growth and extracellular signal-regulated kinase activation decrease. Finally, phenformin withdrawal reverts R-cells phenotype. In summary, our study provides an in vitro model of on-off metabolic switch in melanoma and reveals interesting molecular signatures controlling metabolic reprogramming in this tumour.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalMelanoma Research
Volume30
Issue number1
DOIs
Publication statusPublished - Feb 1 2020

Fingerprint

Phenformin
Oxidative Phosphorylation
Melanoma
Second Primary Neoplasms
Extracellular Signal-Regulated MAP Kinases
Microarray Analysis
Oxygen Consumption
Cultured Cells
Neoplasms
Cell Survival
Phenotype
Pressure
Growth
Genes

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

@article{6d1cb2a11ed04678b361210ac8a271c3,
title = "Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin",
abstract = "Therapeutic failures in cancer therapy are often associated with metabolic plasticity. The use of metabolic modulators as anti-cancer agents has been effective in correcting metabolic alterations; however, molecular events behind metabolic switch are still largely unexplored. Herein, we characterize the molecular and functional events that follow prolonged oxidative phosphorylation inhibition by phenformin in order to study how melanoma cells adapt to this specific metabolic pressure. We show that melanoma cells cultured up to 3 months with high doses of phenformin (R-cells) are less viable and migrate and invade less than parental (S-) cells. Microarray analysis of R-melanoma cells reveals a switch in the energy production strategy accompanied by the modulation of several immunological-associated genes. R-cells display low oxygen consumption rate and high basal extracellular acidification rate. When treated with vemurafenib, R-cell viability, growth and extracellular signal-regulated kinase activation decrease. Finally, phenformin withdrawal reverts R-cells phenotype. In summary, our study provides an in vitro model of on-off metabolic switch in melanoma and reveals interesting molecular signatures controlling metabolic reprogramming in this tumour.",
author = "Mariaelena Pistoni and Giulia Tondelli and Cristina Gallo and Federica Torricelli and Alessandra Maresca and Valerio Carelli and Alessia Ciarrocchi and Katiuscia Dallaglio",
year = "2020",
month = "2",
day = "1",
doi = "10.1097/CMR.0000000000000624",
language = "English",
volume = "30",
pages = "1--13",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin

AU - Pistoni, Mariaelena

AU - Tondelli, Giulia

AU - Gallo, Cristina

AU - Torricelli, Federica

AU - Maresca, Alessandra

AU - Carelli, Valerio

AU - Ciarrocchi, Alessia

AU - Dallaglio, Katiuscia

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Therapeutic failures in cancer therapy are often associated with metabolic plasticity. The use of metabolic modulators as anti-cancer agents has been effective in correcting metabolic alterations; however, molecular events behind metabolic switch are still largely unexplored. Herein, we characterize the molecular and functional events that follow prolonged oxidative phosphorylation inhibition by phenformin in order to study how melanoma cells adapt to this specific metabolic pressure. We show that melanoma cells cultured up to 3 months with high doses of phenformin (R-cells) are less viable and migrate and invade less than parental (S-) cells. Microarray analysis of R-melanoma cells reveals a switch in the energy production strategy accompanied by the modulation of several immunological-associated genes. R-cells display low oxygen consumption rate and high basal extracellular acidification rate. When treated with vemurafenib, R-cell viability, growth and extracellular signal-regulated kinase activation decrease. Finally, phenformin withdrawal reverts R-cells phenotype. In summary, our study provides an in vitro model of on-off metabolic switch in melanoma and reveals interesting molecular signatures controlling metabolic reprogramming in this tumour.

AB - Therapeutic failures in cancer therapy are often associated with metabolic plasticity. The use of metabolic modulators as anti-cancer agents has been effective in correcting metabolic alterations; however, molecular events behind metabolic switch are still largely unexplored. Herein, we characterize the molecular and functional events that follow prolonged oxidative phosphorylation inhibition by phenformin in order to study how melanoma cells adapt to this specific metabolic pressure. We show that melanoma cells cultured up to 3 months with high doses of phenformin (R-cells) are less viable and migrate and invade less than parental (S-) cells. Microarray analysis of R-melanoma cells reveals a switch in the energy production strategy accompanied by the modulation of several immunological-associated genes. R-cells display low oxygen consumption rate and high basal extracellular acidification rate. When treated with vemurafenib, R-cell viability, growth and extracellular signal-regulated kinase activation decrease. Finally, phenformin withdrawal reverts R-cells phenotype. In summary, our study provides an in vitro model of on-off metabolic switch in melanoma and reveals interesting molecular signatures controlling metabolic reprogramming in this tumour.

UR - http://www.scopus.com/inward/record.url?scp=85075562375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075562375&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000624

DO - 10.1097/CMR.0000000000000624

M3 - Article

C2 - 31116160

AN - SCOPUS:85075562375

VL - 30

SP - 1

EP - 13

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -